Skip to main content

Table 3 In vitro experiment conditions

From: An integrated pharmacokinetics ontology and corpus for text mining

Experimental Conditions: Drugs Substrate, metabolite, and inhibitor/inducer FDA Drug Interaction Guidance, 2006
Metabolism Enzymes Buffer Salt composition  
EDTA concentration
MgCl2 concentration Cytochrome b5 concentration  
NADPH source Concentration of exogenous NADPH added isocytrate dehydrogenase + NADP  
protein Non-recombinant enzymes Microsomes (human liver microsomes, human intestine microsomes, S9 fraction, cytosol, whole cell lysate, hepatocytes)  
Recombinant enzymes Enzyme name mg/mL or uM  
genotype   
Transporters Bi-Directional CHO; Caco-2 cells; HEK-293; Hepa-RG; LLC; LLC-PK1 MDR1 cells; MDCK; MDCK-MDR1 cells; Suspension Hepatocyte  
Transport  
Uptake/efflux tumor cells, cDNA transfected cells, oocytes injected with cRNA of transporters  
ATPase membrane vesicles from various tissues or cells expressing P-gp, Reconstituted P-gp  
Other factors Pre-incubation time  
Incubation time  
Quantification methods HPLC/UV, LC/MS/MS, LC/MS, radiographic  
Sample size  
  Data Analysis log-linear regression, plotting; and nonlinear regression